Patent · US Active

Thienopyrimidines having Mnk1/Mnk2 inhibiting activity for pharmaceutical compositions

US8633201B2 · kind B2 · utility

3Cited by

5References

12Claims

0Family size

Assignee

Boehringer Ingelheim International GmbH · DE

Inventors

Babette Aicher · Frankfurt am Main, DE
Thomas Coulter · Wantage, GB
Stefan Jaekel · Oettingen, DE
Arndt-Rene Kelter · Bornheim, DE
Stephen Murfin · Biggenden, AU
Tanja Reuter · Darmstadt, DE
Steven John Taylor · Winchester, US

Key dates

Filing date	Apr 10, 2007
Grant date	Jan 21, 2014
Priority date	—
Expiry date	Feb 23, 2029

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to novel pharmaceutical compositions comprising thienopyrimidine compounds. Moreover, the present invention relates to the use of the thienopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.